Food technology company Holista Colltech (ASX: HCT) has filed a patent for platform technology claiming to deliver fat-soluble medications which can be applied to the cannabidiol oil industry, making CBD oils 40 times more potent.
If granted, the global patent can be applied to a whole range of molecules to create a water-soluble delivery system with the company expecting CBD producers to be prime beneficiaries from use of the tech to produce lower dosages.
“Working on developing this technology is exciting. Most medicine consumed orally is wasted due to its poor absorption by the body,” said head of Holista’s Technical Advisory Panel, Dr Roscoe Moore Jr.
“This is especially true for CBD, which is also expensive. More important, the integrity of the final molecule is preserved exactly as it is found in nature and hence, there is no apparent need for any lengthy approvals process anywhere in the world.”
With increasing adoption rates and acceptance around the medical benefits of cannabis globally, many clinical trials are underway showing CBD to have favourable effects in patients with inflammation, pain, psychosis or mental disorders, inflammatory bowel disease, nausea, migraines, depression and anxiety.
Extracted from cannabis, CBD is a non-psychoactive cannabinoid which is different to Tetrahydrocannabinol (THC) which is the chemical compound associated with psychoactive effects.
In conjunction with the global patent filing, Holista has commenced discussions with CBD producers in North America with a view of developing a commercial model around their platform technology. Initial plans from the Company will be to offer it to producers for an access fee followed by ongoing licensing fees.
Beyond this development work in the CBD space, Holista is focused on fat-soluble substances including curcumin and Vitamin D, targeting initially the food and nutraceutical markets.
Throughout 2019, Holista has developed and manufactured various low Glycaemic Index (low‐GI) food products including flatbreads and noodles for export throughout Asia which has resulted in strong cash flow for the Company.
For the Quarter ending 30 June 2019, Holista reported revenues of $2.15m for its first cash flow positive Quarter of FY19.
Biotech company Biotron Limited (ASX:BIT) has announced a bold step into the anaesthetics sector, acquiring…
DroneShield (ASX:DRO) is expanding its Australian footprint with a $13 million investment to establish a…
Australian fintech Stakk (ASX:SKK) has signed a three-year agreement with U.S. telecommunications giant T-Mobile USA,…
Australia’s mental health burden is growing – and one of the toughest challenges is treatment-resistant…
NoviqTech Limited (ASX:NVQ) has taken a decisive step into the quantum computing market, unveiling the…
Brazilian Rare Earths Limited (ASX:BRE) has cleared its last regulatory hurdle to begin pilot operations…